2SeventyBio's partner pauses early-stage cancer study
June 14 (Reuters) - 2SeventyBio TSVT.O on Wednesday said its partner had paused an early-stage cancer study in response to a recent death in the trial. (Reporting by Pratik Jain; Editing by Devika Syamnath) ((Pratik.Jain@thomsonreuters.com;))
Recent news on 2Seventy Bio
See all news2Seventy Bio Inc expected to post a loss of 17 cents a share - Earnings Preview
2Seventy Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: 2Seventy Bio Q4 Basic EPS USD -0.37
2Seventy Bio Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney